Hana Biosciences:Eine große Story nimmt ihren Lauf

Auch in Frankfurt und München auf Tageshoch. Hat sich ein sehr schöner Trend gebildet. Nun wird sie wie von allein laufen in den kommenden Wochen.

;-)

In der letzten Ausgage von "der Aktionär" ist ein sehr positiver Bericht und Interview mit dem Vorstandschef Mark Ahn. Trägt vielleicht ein bißchen zur positiven Entwicklung bei. Grüße vom Waleshark.  

Der gesamte Biotech-Sektor ist heute schwach, sodass es völlig normal ist, dass Hana mit dem Markt etwas fällt.  

Sehr geringes Volumen heute. Ist ein gutes Zeichen: Anstieg in den letzten Tagen bei hohem Volumen, Konsolidierung bei geringem Volumen. Ist die Basis für einen langfristigen Aufwärtstrend!;-)

Wochengewinn innerhalb so kurzer Zeit futsch ist, ist das für mich keine gesunde Konsolidierung sondern ganz einfach ein herber Rückschlag. Wer etwas schönredet belügt sich selber. Sicher bn ich jetzt enttäuscht vom Kursverlauf, denn ich hatte gehofft wie gehen mit 6,4xx in`s Wochenende. Volumen hin Volumen her, Fakt ist doch ein krasses absacken bis über 8%, jetzt immer noch 6%. Ich habe jedenfalls unter 5,83 noch ein Limit gesetzt um noch mal etwas zu verbilligen. Könnte nächste Woche durchaus noch weiter runtergehen. Ich glaube wie Du an den Wert aber Hana ist nunmal extrem volatil. Außerdem fahre ich am Sonntagmittag in den Urlaub und lasse einfach laufen. Mal sehen wie`s ausschaut, wenn ich in 14 tagen wiederkomme. Bis dahin viel Glück.
Grüße vom Waleshark.

Wenn du mit ana nur kurzfristig denkst, ist es für dich natürlich nicht so toll.

Wer an die Story glaubt (so wie ich), den wird es in einigen Jahren kaum jucken, ob man zu 5,80€ oder zu 6,50€ eingestiegen ist. So nutzt man solche Chancen eben zum Nachkaufen. Wenn man sich den Chart anschaut, erkennt man auch schön, dass in allen Aufwärtsperioden immerwieder einzelne Tage vorkamen, an denen es mehrere Prozente abwärts ging. Völlig normal und ok. Wenn du mit sowas nicht leben kannst und willst, solltest du dir besser DAX-Werte ins Depot legen!;-)

Waren wohl die Meisten schon im Wochenende!*lach*

Wie gehts hier weiter?

7,40USD scheint SK zu sein.

@Nukem: Du, Kursziele anzugeben ist nicht meine Sache. Alles schwer abzuschätzen.

Aber wie ich schon mehrfach geschrieben habe, sehe ich das sehr langfristig (mehrere Jahre). Der gute Newsflow sollte anhalten und da man die Zulassung von Zensana bei der FDA inzwischen beantragt hat, rechne ich hier noch im Herbst mit der Zulassung. Sollten weitere Blockbuster, die sich momentan in den verschiedenen klinischen Phasen befinden (Pipeline weiter oben im Thread), wird Hana in neue Regionen (kurstechnisch und umsatzmäßig) vordringen. Also persönlich bin ich davon überzeugt, dass man sein Geld auf Sicht von ein paar Jahren hier vervielfachen können wird.

Macht ja nix. ;-)Kannst du ja ruhig haben. Mir wäre es aber zu langweilig. Ich brauche den Nervenkitzel. Freue mich auch schon auf die kommende Woche, weil dann German Brokers abgehen wird!;-)

Schönes Wochenende!

Die Voraussetzungen für einen nachhaltigen Aufschwung sieht Ahn als gegeben: Der Antrag auf Zulassung des Medikamentes Zensana wurde fristgerecht zum 30. Juni 2006 bei den US-Behörden eingereicht. Mit der Zulassung, für das Mittel, das gegen Übelkeit und Erbrechen bei Chemotherapie eingesetzt werden soll, rechnet Hana im ersten Halbjahr 2007. Bis Ende dieses Jahres will Hana die Erlaubnis von der US-Gesundheitsbehörde FDA erhalten, mit den Phase-III-Tests mit dem potenziellen Blutkrebsmittel Marqibo zu beginnen. Den experimentellen Wirkstoff hatte Hana erst im Mai 2006 von der Firma Inex einlizenziert. Auch bei Talotrexin, das unter dem Namen Talvesta verkauft werden soll, verläuft die Entwicklung planmäßig. Zum Ende dieses Jahres will Hana Daten aus einer laufenden Studie der Phase II präsentieren. In dieser wird Talvesta auf seine Eignung zur Behandlung von Lungenkrebs geprüft. Am Geld wird die erfolgreiche Fortentwicklung der Produktkandidaten nicht scheitern: Nach mehreren erfolgreichen Kapitalmaßnahmen ist die Hana-Kasse mit rund 50 Millionen Dollar gut gefüllt.
Schlechtes Timing

Die Kaufempfehlung im Juni hat sich im Nachhinein als zu früh erwiesen, wie die jüngste Talfahrt bewiesen hat. Dies ändert jedoch nichts an den langfristig sehr guten Perspektiven für das Unternehmen. Risikobereite Anleger nutzen deshalb das aktuelle Niveau zum Aufbau einer kleinen Position.

Erschienen in DER AKTIONÄR Ausgabe 32/2006.

Wie geschrieben war es am Freitag nur eine kleine, gesunde Konsolidierung, damit der langfristige Aufwärtstrend auf solideren Füßen steht.

Schöner Doppelboden wurde gebildet und im Moment geht es mächtig hoch bei steigenden Umsätzen in USA!!:-)

Schluss fast auf Tageshoch. Damit könnte die Bodenbildung abgeschlossen sein und wir bilden ein schönes "W"!

"In the second quarter of 2006, we achieved a significant number of clinical, regulatory and business development milestones," said Mark J. Ahn, Ph.D., President and CEO of Hana. "We are pleased to have completed and submitted our NDA for Zensana(TM) as we believe this product has the potential to offer a convenient and attractive alternative to those patients suffering from chemotherapy, radiotherapy, and post-operative induced nausea and vomiting. In addition we doubled the size of our product pipeline during the quarter as a result of our transaction with Inex, while advancing several clinical-stage programs on schedule with corporate timelines."

A reconciliation(2) between non-GAAP and GAAP earnings per share for the second quarters of 2006 and 2005 is provided in the following table:

--------------------------------------------------            Reported      Employee         Costs        Non-GAAP           GAAP Basic      Stock         Associated    Basic and           and Diluted   Compensation    with Inex      Diluted              EPS          Expense       Acquisition     EPS--------------------------------------------------Q2 2006     ($0.81)        $0.09           $0.48         ($0.26)--------------------------------------------------Q2 2005     ($0.13)        $0.00           $0.00         ($0.13)--------------------------------------------------YTD 2006    ($1.00)        $0.11           $0.50         ($0.41)--------------------------------------------------YTD 2005    ($0.29)        $0.00           $0.00         ($0.29)--------------------------------------------------
Note: Amounts may not sum due to rounding.

Key Achievements in Second Quarter 2006

-- Announced the submission of a New Drug Application (NDA) for Zensana (ondansetron HCl) Oral Spray to the U.S. Food and Drug Administration (FDA) seeking marketing approval for the prevention of nausea and vomiting associated with chemotherapy, radiotherapy and post-operative induced nausea and vomiting. If approved, Hana targets commercial launch of Zensana in the United States in the first half of 2007.

-- Initiated a multicenter, multinational Phase II clinical trial with Talvesta(TM) (talotrexin) in relapsed or refractory non-small cell lung cancer (NSCLC).

-- Completed licensing of three additional targeted cancer drug candidates from Inex Pharmaceuticals.

-- Presented Phase I clinical results in solid tumors and NSCLC with Talvesta at the 2006 American Society of Clinical Oncology (ASCO) Annual Meeting.

-- Presented pivotal trials confirming Zensana(TM) (ondansetron HCl) Oral Spray 8 mg dose is statistically bioequivalent to the current commercially available 8 mg ondansetron tablet at the ASCO Annual Meeting.

-- Presented new survey results at the ASCO Annual Meeting which indicated medical oncologists, radiation oncologists and oncology nurses surveyed believe Zensana may be an attractive formulation for patients with chemotherapy and radiotherapy induced nausea and vomiting.

-- Announced that the FDA granted orphan drug designation for Talvesta in patients with acute lymphoblastic leukemia (ALL).

-- Announced that the FDA granted orphan drug designation for Ropidoxuridine (IPdR) for the treatment of malignant glioma, which makes up approximately half of all primary brain tumors.

-- Announced that Hana joined the Russell 3000(R) Index and the Russell Microcap(TM) Index on June 30, 2006.

-- On April 17, 2006 Hana's common shares began trading on the NASDAQ Global Market (formerly the NASDAQ National Market) under the symbol HNAB.

Hana Biosciences' management will host a live webcast to include a discussion of earnings and a business update at 5:30 am PDT, 8:30 am EDT. Those interested in hearing management's discussion may join the call by dialing (866) 585-6398 in the US/Canada. International participants may access the call by dialing (416) 849-9626. Participants may also access a live webcast of the conference call on Hana's website at www.hanabiosciences.com.

An audio replay will be available until August 21, 2006 following the call by dialing (888) 566-0813 US/Canada and (402) 220-2507 for International participants. Enter #4111557 when prompted for the playback access code. The webcast will be available via the company's website until August 28, 2006.

Reconciliation of GAAP to Non-GAAP Net Loss:

GAAP refers to generally accepted accounting principles in the United States of America. Hana's non-GAAP net loss and loss per share excludes the impact of the one-time upfront fees paid to Inex Pharmaceuticals Corp. and transaction fees paid as part of its acquisition and stock option expense related to implementation of FAS 123R. We are reporting non-GAAP results in addition to, and not as a substitute for, financial measures calculated in accordance with GAAP. The Company provides these non-GAAP numbers to facilitate a comparison of our business from period to period and to allow investors to analyze our business results using the same measures our management uses to evaluate our operating performance. We encourage investors to carefully consider our results under GAAP, as well as our non-GAAP reconciliation between these presentations to more fully understand our business.

(1) The company adopted Statement of Financial Accounting Standards No. 123R (or FAS 123R) on a modified prospective basis beginning January 1, 2006. As a result, no employee stock-based compensation expense using FAS 123R has been recognized in GAAP-reported amounts in any prior period.

(2) Hana's non-GAAP net loss and non-GAAP loss per share excludes the impact of the one-time upfront fees paid to Inex Pharmaceuticals and transaction fees paid as part of its acquisition of three product candidates. The differences in non-GAAP and GAAP numbers are reconciled in the accompanying tables.

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (NASDAQ:HNAB) is a South San Francisco, CA-based biopharmaceutical company that acquires, develops, and commercializes innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Hana's product candidates, the risk that the results of clinical trials may not support Hana's claims, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing pharmaceutical products. Additional risks are described in the company's most recently filed Form 10-K and Form 10-Q. Hana assumes no obligation to update these statements, except as required by law.

                       HANA BIOSCIENCES, INC.                     (A DEVELOPMENT STAGE COMPANY)                       CONDENSED BALANCE SHEETS                                            June 30,    December 31,                                              2006          2005                                          ------------- --------------ASSETS                                     (Unaudited)Current assets:Cash and cash equivalents                 $ 44,266,298  $  17,082,521Short term investments                       2,332,051        472,000Prepaid expenses and other current assets       69,744         74,729                                          ------------- --------------   Total current assets                     46,668,093     17,629,250Property and equipment, net                    323,899         76,496Other assets                                        --         20,453 Restricted cash                               125,166             --                                          ------------- -------------- Total assets                             $ 47,117,158  $  17,726,199                                          ============= ==============LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable                          $  1,091,750  $     671,491Accrued expenses                             2,742,488        865,135                                          ------------- -------------- Total liabilities                           3,834,238      1,536,626                                          ------------- --------------Commitments and contingencies Stockholders' equity:  Common stock to be issued                    185,841             --  Common stock; $0.001 par value  100,000,000 shares authorized;   28,742,784 and 22,348,655 shares   issued and outstanding at June 30,   2006 and December 31, 2005,   respectively                                 28,743         22,349Additional paid-in capital                  85,372,186     34,400,345Accumulated other comprehensive loss           (96,000)      (164,000)Deficit accumulated during the development stage                         (42,207,850)   (18,069,121)                                          ------------- --------------   Total stockholders' equity               43,282,920     16,189,573                                          ------------- --------------Total liabilities and stockholders' equity                                   $ 47,117,158  $  17,726,199                                          ============= ==============                        HANA BIOSCIENCES, INC.                     (A DEVELOPMENT STAGE COMPANY)       CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS                              (Unaudited)                                              Three Months Ended                                                    June 30,                                          ----------------------------                                              2006           2005                                          ------------- --------------Operating expenses:General and administrative                $  2,576,308  $     963,270Research and development                    18,368,374      1,150,447                                          ------------- --------------Total operating expenses                    20,944,682      2,113,717Loss from operations                       (20,944,682)    (2,113,717)                                          ------------- --------------Other income (expense):Interest income, net                           249,426         30,495Other expense, net                              (8,800)        (2,633)                                          ------------- -------------- Total other income (expense)                  240,626         27,862                                          ------------- --------------Net loss                                  $(20,704,056) $  (2,085,855)                                          ============= ==============Net loss per share, basic and diluted                                  $      (0.81) $       (0.13)                                          ============= ==============Shares used in computing net loss per share, basic and diluted                                    25,640,398     15,726,776Comprehensive loss:Net loss                                  $(20,704,056) $  (2,085,855)Unrealized gain (loss)                        (156,000)             -                                          ------------- --------------Comprehensive loss                        $(20,860,056) $ (2,085,855)                                          ============= ==============                                                          Cumulative                                                         Period from                                                         December 6,                                                            2002                                                         (date of                                Six Months Ended         inception)                                    June 30,                to                           ---------------------------    June 30,                               2006          2005           2006                           ------------- ------------- ---------------Operating expenses:General and administrative $  3,560,283  $  1,670,483  $   10,393,865Research and development     20,946,506     2,872,172      32,360,602                           ------------- ------------- ---------------Total operating expenses     24,506,789     4,542,655      42,754,467Loss from operations        (24,506,789)   (4,542,655)    (42,754,467)                           ------------- ------------- ---------------Other income (expense):Interest income, net            384,752        50,062         583,533Other expense, net              (16,692)      (10,137)        (36,916)                           ------------- ------------- --------------- Total other income  (expense)                     368,060        39,925         546,617                           ------------- ------------- ---------------Net loss                  $ (24,138,729) $ (4,502,730) $  (42,207,850)                           ============= ============= ===============Net loss per share, basic and diluted                      (1.00) $      (0.29)                           ============= =============Shares used in computing net loss per share, basic and diluted                 24,037,103    15,402,248Comprehensive loss:Net loss                   $(24,138,729) $ (4,502,730)Unrealized gain (loss)           68,000             -                           ------------- -------------Comprehensive loss         $(24,070,729) $ (4,502,730)                           ============= =============
SOURCE: Hana Biosciences, Inc.

Hana Biosciences, Inc. Remy Bernarda, 650-228-2769 (Investor & Media) Fax: 650-588-2787 investor.relations@hanabiosciences.com

Copyright Business Wire 2006


Quelle: www.stockhouse.com/news/news.asp?newsid=3844331&tick=HNAB

.

.

Sieht so aus, als würde sich nun ein "W" wie wunderschön bilden! Damit stimmt die Richtung wieder!:-)

.

.

D 5,76€
USA $7.34

.